Celanese and Secarna Join Forces to Develop Long-Acting Implants for Drug Delivery

Celanese Corporation, a globally renowned chemical and materials company, has recently announced an exciting new research collaboration with Secarna Pharmaceuticals GmbH & Co. KG to focus on the development of long-acting implants for delivering antisense oligonucleotides (ASOs). The objective of this partnership is to establish a more efficient and patient-friendly method for treating a variety of diseases by reducing dosing frequency and minimizing immune responses.

ASOs are artificial molecules designed to target specific messenger RNA and impede the production of disease-related proteins. Although this approach shows potential, it often necessitates frequent administration or large doses, which can be burdensome for patients.

This collaboration will harness Celanese’s VitalDose® Drug Delivery Platform in conjunction with Secarna’s proprietary ASO Drug Discovery and Development Platform. The VitalDose® technology is recognized for its dependable controlled-release performance and is already utilized in approved drug products in the U.S. and Europe, capable of delivering medications for prolonged periods, potentially up to several years.

Cyonna Holmes, the global business strategy leader for Ophthalmology and RNA at Celanese, conveyed excitement about the potential of developing an innovative implant that could transform the administration of disease-modifying ASO therapies. Konstantin Petropoulos, Secarna’s Chief Business Officer, also expressed enthusiasm and underscored the objective to provide highly specific, potent, safe, and convenient therapeutic options to patients in need.

The research will be conducted partly at the Celanese Development & Feasibility Lab, showcasing the company’s pharmaceutical expertise.

Celanese, a Fortune 500 company with net sales of $10.9 billion in 2023, is widely recognized for its specialty material solutions across various industries, with a strong focus on sustainability and community impact. On the other hand, Secarna Pharmaceuticals is a frontrunner in antisense drug discovery and development in Europe, with over 20 programs targeting various diseases.

This collaboration represents a significant advancement in drug delivery technology and highlights the dedication of both companies to enhancing patient care through innovation. The information for this article is derived from an official press release statement.

In conclusion, the partnership between Celanese and Secarna marks a promising development in the realm of drug delivery technology. The potential advantages of long-acting implants for delivering ASOs could have a substantial impact on patient care, offering a more convenient and effective treatment option for various diseases. With both companies contributing their expertise and resources, this collaboration holds great promise for the future of therapeutic innovation.